ArticleCardiovascular diagnosis and therapy2025
Diabetes management dilemma: association between glycated hemoglobin levels and mortality risk in diabetic patients.
Article in Cardiovascular diagnosis and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between improved glycemic control and mortality reduction in diabetes remains controversial. This study aimed to examine the temporal trends and association between haemoglobin A1c (HbA1c) control status and mortality risk among adults with diabetes. Methods: This study utilized data from the National Health and Nutrition Examination Survey (NHANES) collected between 1999 and 2014. The statistical significance of linear or nonlinear trends was evaluated using logistic regression. Nonlinear temporal trends were evaluated by including quadratic terms for time in the regression models. To explore the relationships between HbA1c and mortality, the study employed the Cox proportional hazards model for multivariate analysis, along with Kaplan-Meier survival curves for univariate visualization. Results: With 6,516 participants, the study showed a significant improvement in the control rate of HbA1c among diabetic patients, increasing from 41.61% in 1999 to 58.72% in 2014 (P<0.001). However, there was no noticeable trend in the overall all-cause mortality rate, which was 10.79% in 1999 and 12.08% in 2014 (P=0.608), or in cardiovascular mortality, which was 4.74% in 1999 and 4.24% in 2014 (P=0.371), among diabetic patients. No significant differences were found in the risks of all-cause mortality [hazard ratio (HR): 0.64; 95% confidence interval (CI): 0.36-1.13; P=0.13] or cardiovascular mortality (HR: 1.11; 95% CI: 0.41-3.02; P=0.84) between patients with HbA1c below 7.0% and those with HbA1c 7.0% or higher. Interestingly, the rate of sulfonylureas use went down from 30.25% in 1999 to 12.42% in 2014 (linear P value <0.001). Conclusions: Despite significant improvements in HbA1c control rates among US adults with diabetes from 1999 to 2014, we observed no corresponding reduction in 5-year mortality risks. Achieving HbA1c <7.0% was not associated with lower mortality risk in this population. These findings suggest that improvements in glycemic control alone may be insufficient to reduce mortality in diabetic populations, highlighting the need for a more comprehensive approach to diabetes management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.